Redipor Success Drives Cherwell Cleanroom Expansion
Cherwell Laboratories, leading supplier of microbiology media and instruments for pharmaceutical and related industries, is continuing with the investment and expansion programme of its cleanroom production facilities. To increase capacity for future demand from Cherwell’s ever growing customer base, Phase II of the expansion programme will boost Redipor microbiological prepared media plate filling and bottle production capabilities. The new cleanroom facility will be further extended by 230 m2 to more than 950 m2.
Once Phase II is completed in early 2014, Cherwell’s facilities will have doubled in size since July 2012. Phase I delivered new inspection and packing facilities to maintain stringent quality requirements in media preparation prior to Phase II’s increase in Redipor production facilities. Uniquely, to ensure utmost quality Cherwell do not package Redipor products straight from the filling line but first hold them to condition, additionally all products then undergo 100% inspection before final packing.
Demand for Cherwell’s Redipor products continues to rise as new customers experience the benefits of a flexible and reliable supply of these exceptionally high-quality prepared media products. Cherwell’s ability to deliver high volume efficiency with small volume flexibility has helped to increase its market share and develop more export markets, such as Poland. Careful selection of new partners in mainland Europe, has also contributed to securing new customers keen to benefit from a full adaptable service for their industrial microbiological prepared media.
Andy Whittard, Managing Director, Cherwell Laboratories, provided further insight into the reasons for Cherwell’s expanding market. “Despite growing interest in rapid methods, the traditional methods for environmental monitoring are still the most widely used and will continue to be for many years to come. This, coupled with some customers’ movement back to UK and European-based manufacturing, is seeing demand for prepared media continue to increase.”
As Cherwell’s production volumes increase from the current 6.5 million agar plates annually, the company will continue to add to its workforce to maintain its efficiency in supply. Cherwell has already recruited five new staff members since the completion of Phase I, with three additional new starters anticipated before the end of 2013.
“Phase II of our cleanroom extension will provide additional manufacturing space to allow us to invest in further production equipment, such as large scale plate filling systems, media preparators and autoclaves,” added Andy Whittard. “By carefully planning and controlling the works around our own production schedules and with our contractor, Envair Projects, we aim to minimise any impact to customers and product lead times.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...